21 articles for MA Convery
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.
Glaxosmithkline
New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.
University of Ljubljana
Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.
Glaxosmithkline
Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.
Glaxosmithkline
Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs.
Glaxosmithkline
The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs.
Glaxosmithkline
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs.
Glaxosmithkline
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
Glaxosmithkline
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.
Gsk Medicines Research Centre
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Glaxosmithkline
Selective and dual action orally active inhibitors of thrombin and factor Xa.
Glaxosmithkline
Sulfonamide-related conformational effects and their importance in structure-based design.
Glaxosmithkline
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
Glaxosmithkline R&D
Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ.
Gsk Medicines Research Centre
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.
Glaxosmithkline
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
Glaxosmithkline
Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
Banyu Tsukuba Research Institute